Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by MYSTICALon Nov 23, 2015 9:21am
244 Views
Post# 24315341

Industry trend....

Industry trend....
AstraZeneca and Sanofi announced a first-of-its-kind deal Thursday night to share more than 200,000 chemical compounds in an effort to speed up drug development. This is encouraging for a highly competitive industry, averse to sharing a piece of gum without a royalty fee tied to breath freshness, let alone compound libraries that were once prized possessions. No money will change hands. Each firm can develop molecules in the other's library with no future obligation. To read the entire article, go to https://www.bloomberg.com/gadfly/articles/2015-11-20/astrazeneca-sanofi-sharing-molecule-libraries-a-good-start
Bullboard Posts